			386						
FORM PTO	D-1449	(Modified)	Atty.	Atty. Docket No. PH1015DB			Serial No. Notyctknown		
II.		ON DISCLOSURE BY APPLICANT	Appli	Applicants: Dolle et al.					
(37 CFR 1.9	98(b))		Filing	Filing Date: December 8, 1997			Group: 1613		
			U.S. PA	TENT DOCU	MENTS				
Examiner		Patent	Issue	sue		Filing	Date		
Initial		Number	Date	Patentee	Class	Subclass	If Appropriate		
DI	AA	5,120,718	6/9/92	Goldman et al.	514	32			
	1	5,120,110	0,7,7	- COLUMN CO UNI		1 2			
	1								
FO	DREI	GN PATENT O	R PUBI	T	IGN PA	TENT AP			
		Document Number	Date	Country or Patent Office	Class	Subalasa	Translation Subclass YES NO		
	+	Number	Date	ratent Office	Class	Subclass	TES	NO	
	-	 		 		 		-	
	 					 			
		2	-) <u> </u>	(-22		2007-01	
						<u> </u>			
		(including Auth		IER DOCUME Date, Relevant Pa		e of Publicati	ion)		
	CA							Clinical	
Dk		Rich et al., "Design and Discovery of Aspartyl Protease Inhibitors Mechanistic and Clinical Implications," In Conformationally Directed Drug Design, Julius A. Vida and Maxwell Gordon, eds. ACS Symposium Series, American Chemical Society, Washington, D.C., Chapter 10, pp.							
	<u></u> _	211-237, 1984.							
				-					
Examine	r: _	DOMINIC	K	EATING	Date C	Considered	: 6/1	7/98	

EXAMINER: Initial citation considered. Draw line through citation not in conformance and not considered. Include copy of this form with next communication to applicant.